Business Development

Business development is a vital part of our corporate strategy. We constantly seek strategic collaborations with companies and academia to enhance value and complement BTI’s programs, including:

Strategic Partnerships

Clinical combination with BXCL701 with other I/O and targeted agents including but not limited to CAR-T and cancer vaccines

Out-licensing

Regional commercialization rights for BXCL501 and BXCL701 programs

In-licensing

Molecules with clinical safety data

We are interested in investigational molecules with established clinical safety data that complement our pipeline and therapeutic areas.

To inquire about collaborative opportunities with BTI, please contact our business development team bd@bioxceltherapeutics.com.